About-2.png

Paving the way to lower drug costs for all Americans.

Why BrightPath

Bright Path Labs vision is to bring our advanced manufacturing technologies to the entire pharmaceutical industry where our cutting edge and proprietary chemical production techniques can significantly contribute to solving some of today’s biggest healthcare challenges, including:​

•    Improving the resiliency of domestic supply chains and the affordability of medicine
•    Reducing the risk of life-saving drug shortages
•    Supplying increased access to medicine for underserved and overlooked patient populations. 

BrightPath-graphics-2.jpg
BPL-Photo-2.jpg

Bright Path Labs' vision is to bring our advanced manufacturing technologies to the entire pharmaceutical industry where our cutting edge and proprietary chemical production techniques can significantly contribute to solving some of today’s biggest healthcare challenges, including:​

  • Improving the resiliency of domestic supply  chains and the affordability of medicine

  • Reducing the risk of life-saving drug shortages

  • Supplying increased access to medicine for underserved and overlooked patient populations 

BrightPath-graphics-4.jpg

Bright Path Labs uses a revolutionary and patented AI-powered continuous-flow manufacturing technology to make and scale molecules faster, more efficiently, and less expensively than traditional batch techniques.

Working in partnership with the FDA Emerging Technology Team to deploy advanced continuous manufacturing technologies, Bright Path Labs'
AI-powered continuous flow technology significantly improves quality control, reduces waste, facilitates manufacturing scale-up, and improves process economics and cost control, saving customers time and money, while reducing supply chain disruption.

Untitled-1.jpg
BrightPath-graphics-5.jpg
shutterstock_691546471.jpg

Bright Path Labs also works with the EPA and industry leaders in AI and ML technologies to ensure our facilities have the highest regulatory compliance, lowest environmental impact, and smallest manufacturing footprint on the planet.

Bright Path Labs is collaborating with philanthropic groups, small businesses and several pharmaceutical and generic medicine companies to translate outdated batch production processes into Bright Path Labs' patented spinning in tube technology (STT®) continuous flow platform. These projects include both novel and already marketed drugs.

Bright Path Labs maintains a development facility in Santa Fe, New Mexico, with larger manufacturing capabilities in North Carolina to commercialize the STT® flow reactor process. Our streamlined process allows drugs to get through the FDA approval process and onto the market faster, which is crucial not only for making sure patients have the medicines they need but also to maintain the international competitiveness of the U.S. pharmaceutical industry.

BrightPath-graphics-6.jpg

Mission

Bright Path Labs is committed to bringing our unique and patented continuous flow reactor technology to the pharmaceutical industry to enhance domestic production of active pharmaceutical ingredients, deliver high-quality and affordable medicine for all, increase access to rare/orphan disease treatments, and empower precision medicine.

We make medicines for those where others can’t or won’t – affordably, safely, securely, and in an environmentally responsible manner.   

about-4.3.jpg

Leadership

Bright Path Labs leadership has significant scientific and technical expertise in
the areas of chemical reaction design, green chemistry, and process evaluation. This includes the successful development of 32 chemistry/API methods with
Bright Path Labs STT® technology spanning commodity and specialty organic chemicals, pharmaceuticals, electronic applications, and nanotechnology.

Tony-Quinones.jpg

Tony Quiñones

CEO & Board Member

Tony Quiñones brings 20+ years of experience in entrepreneurship, venture capital investing, and building operating teams with key expertise in commercializing platform technologies such as Bright Path Labs Inc.

Michael-A.-onzalez.jpg

Michael A. Gonzalez

Chief Scientific Officer & Board Member

Michael A. Gonzalez brings over 25+ years industry experience with the last 20 years at the US Environmental Protection Agency’s Office of Research and Development (“ORD”) as a Senior Supervisory Chemist and Senior Advisor for Green Chemistry.

Phil-Lichtenberger-li-b-w.jpg

Phil Lichtenberger

COO & Board Member

Phil Lichtenberger is a co-founder of Bright Path Labs and brings over 40 years of general management experience as well as high-tech experience working across operations, finance, sales, marketing, and engineering functions.

Larry-Taber.jpg

Larry Taber

CTO & Head of Quality

Larry Taber brings 40 years of biotech, pharmaceutical, and medical device experience in private start-up and top 10 multinational companies.

John-Allen-Jr.jpg

John E. Allen Jr.

Chief Commercialization Officer & Board Member

John E. Allen Jr. brings over 30+ years’ experience in the life sciences and financial services sectors. John is the former CEO of Vault Pharma, an immunology biotechnology company.

Todd-Smith.jpg

Todd N. Smith

CBP & Board Member

Todd N. Smith has 20+ years of pharmaceutical, medical device and biotechnology general management experience and a long track record of building companies and achieving commercial and business development excellence.

Matt-Demaray-b-w-li.jpg

Matt Demaray

Corporate Development

Matt Demaray is a senior business leader who brings nearly 20 years’ experience focused primarily on investments, specialty finance, entrepreneurship, and management consulting.

Dennis-Cope.jpg

Dennis Cope

VP of Engineering

Dennis Cope brings 30+ years of experience in operations management, environmental controls, facility relocations, engineering design, and start-up production/manufacturing projects.

Stephen-Martinez.jpg

Stephen Martinez

SVP, Acquisitions & Economic Development

Stephen Martinez is a real estate investment and development professional with an expertise in tax incentives for development and acquisition.

Board of Directors

John-LaLonde.jpg

John LaLonde

John LaLonde brings over 30 years of general management experience as well as high-tech experience working across operations, sales, manufacturing, and engineering functions.

Marc-Fasteau.jpg

Marc Fasteau

Marc Fasteau is a former partner at New York investment bank Dillon Read and founder and former chairman of the American Strategic Insurance, property & casualty insurance group (sold to Progressive Insurance Corporation in 2015).

Xiping-Su.jpg

Xiping Su, Ph.D

Xiping Su, Ph.D. is the Senior Vice President of Scientific Affairs for ChemWerth, a leading global active pharmaceutical ingredient (“API”) distributor.

Partners

logo-8-pda.png
logo-2-comsol.png
logo-4-fda.png
logo-5-ispe.png
logo-6.2.png
logo-7-medicines-for-all-institute.png
logo-9-quartic-ai.png
logo-10-sparta-systems.png
logo-11-stanford-medicine.png
logo-1-community-association-institute.png
logo-3-epa-usa.png
logo-12.png